First Time Loading...

PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS

Watchlist Manager
PhaseBio Pharmaceuticals Inc Logo
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Watchlist
Price: 0.04 USD 5.26% Market Closed
Updated: May 5, 2024

PhaseBio Pharmaceuticals Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PhaseBio Pharmaceuticals Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Net Income (Common)
-$131.1m
CAGR 3-Years
-76%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$484m
CAGR 3-Years
17%
CAGR 5-Years
-39%
CAGR 10-Years
-20%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$6.7B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
25%

See Also

What is PhaseBio Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-131.1m USD

Based on the financial report for Dec 31, 2021, PhaseBio Pharmaceuticals Inc's Net Income (Common) amounts to -131.1m USD.

What is PhaseBio Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-70%

Over the last year, the Net Income (Common) growth was -33%. The average annual Net Income (Common) growth rates for PhaseBio Pharmaceuticals Inc have been -76% over the past three years , -70% over the past five years .